Chugai Pharmaceutical Co Ltd (4519.T)
7,470JPY
7:00am BST
¥40 (+0.54%)
¥7,430
¥7,400
¥7,490
¥7,380
411,700
711,675
¥7,900
¥5,950
Latest Key Developments (Source: Significant Developments)
Chugai Pharmaceutical and Lilly enter into license agreement for oral GLP-1 agonist, OWL833
Sept 27 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says Chugai Pharmaceutical and Eli Lilly and Company today announced they have entered into a license agreement for OWL833, Chugai’s oral non-peptidic GLP-1 receptor agonist .OWL833 is a Phase 1-ready asset that is being studied for the treatment of type 2 diabetes.Under the terms of the agreement, Lilly will receive worldwide development and commercialization rights to OWL833 .Chugai will receive an upfront payment of $50 million and is eligible for milestone payments based on achievement of certain predetermined milestones.If the molecule is successfully commercialized, Chugai would also be eligible for royalty payments. Full Article
Chugai And Lilly Enter Into Agreement For Type 2 Diabetes Treatment Oral Glp-1 Agonist, Owl833
Sept 26 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>::SAYS CHUGAI AND LILLY ENTER INTO A LICENSE AGREEMENT FOR ORAL GLP-1 AGONIST, OWL833.CHUGAI'S ORAL GLP-1 AGONIST, OWL833, WILL SOON ENTER PHASE I CLINICAL DEVELOPMENT.UNDER THE TERMS OF THE AGREEMENT, LILLY WILL RECEIVE WORLDWIDE DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO OWL833.CHUGAI PHARMACEUTICAL WILL RECEIVE UPFRONT PAYMENT OF $50 MILLION AND IS ELIGIBLE FOR MILESTONE PAYMENTS BASED ON ACHIEVEMENT OF PREDETERMINED MILESTONES.AFTER TRANSACTION, THERE WILL BE NO CHANGE TO LILLY'S 2018 NON-GAAP EARNINGS PER SHARE GUIDANCE.CHUGAI PHARMACEUTICAL - THERE WILL BE NO CHANGE TO CO'S CONSOLIDATED FINANCIALS FORECAST FOR FY ENDING DECEMBER 2018 AS A RESULT OF THAT TRANSACTION. Full Article
Pharma Mar Reaches Early Termination Agreement With Chugai For Zepsyre
June 26 (Reuters) - Pharma Mar SA
Pharma Mar Says Chugai Terminates Licensing Agreement For Zepsyre In Japan
April 27 (Reuters) - Pharma Mar SA
CHUGAI PHARMACEUTICAL says filing of patent infringement lawsuit and petition for provisional disposition order
Jan 9 (Reuters) - CHUGAI PHARMACEUTICAL Co Ltd <4519.T> ::Says it filed an application for assisting intervention with Zenyaku Kogyo Co Ltd in a lawsuit that Genentech Inc filed, wherein the plaintiff demands prohibition of sales etc. of Rituxan® Injection, against Sandoz K.K and Kyowa Hakko Kirin Co Ltd.Says the company has also filed an application for assisting intervention in a petition for provisional disposition order that has been filed with the lawsuit. Full Article
Chiome Bioscience says termination of joint research contract
Dec 18 (Reuters) - Chiome Bioscience Inc <4583.T>:Says it announces termination of candidate antibody related joint research contract, which was signed between the co and CHUGAI PHARMACEUTICAL CO LTD <<<4519.T>>>, as the contract has expired on Dec. 31 . Full Article
Chugai Pharmaceutical says change of chief executive officer
Dec 12 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it names current president and chief operating officer Tatsuro Kosaka as chief executive officer and president, effective late March 2018. Full Article
R&I affirms Chugai Pharmaceutical's rating at "AA-" and says stable outlook -R&I
Nov 16 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-" -R&I.Says rating outlook stable -R&I. Full Article
Marketing and manufacturing right transfer of 13 long-term listed products from Chugai Pharmaceutical to Taiyo Pharma
Nov 14 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it and TAIYO HOLDINGS CO LTD <<<4626.T>>> announced today that they have entered into an agreement, under which the co and F. Hoffmann-La Roche, Ltd. will transfer the marketing authorizations, including marketing and manufacturing rights, of 13 long-term listed products manufactured and marketed in Japan by Chugai to TAIYO Pharma Co., Ltd., a wholly owned subsidiary of Taiyo Holdings. Full Article
Japan's polarised stock market leaves few options for investors
TOKYO The gap in valuations of Japanese shares is at its widest since the dot-com crisis two decades ago and will likely stay that way until global trade tensions ease, analysts say.
Earnings vs. 
Estimates